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ABSTRACT

Comparison of Post-licensure safety surveillance of 13-Valent Pneumococcal
Conjugate vaccine and 7-Valent Pneumococcal Conjugate vaccine: Data from the
Vaccine Adverse Event Reporting System (VAERS).

Background: On February 24, 2010, Food and Drug Administration (FDA) licensed a
13-valent pneumococcal conjugate vaccine (Prevnar 13®, [PCV13]) for use among
children aged 6 weeks--71 months. The Advisory Committee on Immunization Practices
(ACIP) recommended PCV13 routine vaccination of all children aged 2--59 months,
children aged 60--71 months with underlying medical conditions, with PCV13 replacing
PCV7 for all doses.

Methods: We searched case reports to the Vaccine Adverse Event Reporting System
(VAERS), a US passive surveillance system, for adverse events (AEs) reported after
immunization with PCV13 vaccine from February 24, 2010 through February 24, 2011
for persons vaccinated from February 24, 2010 through December 31, 2010 and
compared them with AEs reported by persons who were vaccinated with PCV7.

Results: VAERS received 1503 reports of AEs after PCV13; multiple vaccines were
given in 79.0% of reports. One hundred eighty (11.9%) were coded as serious, including
nineteen reports of death. The most frequently reported symptoms were injection site
reactions, fever, irritability and vomiting. Seven hundred fifty-eight (50.4%) reports

comprised males. Most reports (37.7%) were from children 1-2 years. Total number of
reports received for PCV13 was very similar to those received after vaccination with
PCV7.
Conclusions: AEs reported to VAERS following 13-valent pneumococcal conjugate
vaccine were consistent with AEs previously observed in pre-licensure trials. We did not
identify any major safety concerns or outcomes.
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CHAPTER I

INTRODUCTION

Streptococcus pneumoniae (pneumococcus) is a lancet-shaped, gram-positive, facultative
anaerobic bacteria first isolated by Pasteur in 1881. Pneumococcus is a common leading
cause of bacteremia, meningitis and community acquired pneumonia among all ages, it is
also a major cause of sinusitis and acute otitis media. Across Europe and North America,
30-100 cases of pneumonia per 100,000 people are expected each year (Heymann, 2008).
The highest rates of invasive pneumococcal disease (IPD) occur among young children,
especially those younger than 2 years of age; Bacteremic pneumonia accounts for 12%–
16% of IPD. In the United States (U.S) Pneumococcus has become the leading cause of
bacterial meningitis among children younger than 5 years of age and is a common cause
of acute otitis media; by age 12 months, more than 60% of children have had at least one
episode of acute otitis media (Atkinson et al., 2009).

On February 2000 the Food and Drug Administration (FDA) approved a 7-valent
pneumococcal conjugate vaccine (Prevnar®, PCV7), the first pneumococcal conjugate
vaccine licensed in the U.S to prevent invasive pneumococcal disease. In 2002, two years
after licensure, PCV7 was also indicated and approved for active immunization of infants
against otitis media caused by vaccine serotypes. Prior to licensure randomized clinical
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trials were conducted in infants and children; good vaccine efficacy and a favorable
safety profile were demonstrated (MMWR; December 10, 2010 / 59(RR11); 1-18).
Prior to the introduction of PCV7, in children younger than 2 years the incidence of
invasive pneumococcal disease was 166.9 per 100000 child years in the U.S (Robinson K
et al., 2001). New conjugate vaccines may be able to prevent and reduce the burden of
invasive pneumococcal disease as well as reducing the incidence rates of acute otitis
media in young children

The World Health Organization (WHO) in 2007 recommended all countries to include
pneumococcal conjugated vaccines to their national infant immunization programs
(WHO position paper, 2007).

On February 24, 2010, the FDA licensed a 13-valent pneumococcal conjugate vaccine
(Prevnar 13®, PCV 13), for prevention of IPD caused by the 13 pneumococcal serotypes
covered by the vaccine and for prevention of otitis media caused by serotypes in the 7valent pneumococcal conjugate vaccine formulation (Prevnar®, PCV7) (FDA Product
approval information–CBER, 2010).

PCV13 is made by Pfizer Inc., the manufacturer of PCV7. The formulation and
manufacturing process for the PCV13 vaccine was the same as that used for PCV7
vaccine, and the safety profile of licensed PCV13 was anticipated to be similar to that of
PCV7, which has an excellent safety record.

4

The Advisory Committee on Immunization Practices (ACIP) recommended PCV13 for
routine vaccination of all children aged 2-59 months, children aged 60-71 months with
underlying medical conditions that increase their risk for pneumococcal disease or
complications and children who previously received 1 or more doses of PCV7. PCV13
was slated to be a successor to PCV7 (MMWR; December 10, 2010 / 59(RR11);1-18).

An important factor to assess during pre-licensure is the detail evaluation of vaccine
safety. For PCV7 and PCV13 no major safety problems were identified, however it is
impossible to identify all safety concerns during clinical trials and there is always a
possibility of not detecting some unusual adverse events. Clinical trials and postlicensure safety surveillance are critical to maintaining public health and trust in the
Pneumococcal 13-valent Conjugate Vaccine. Due to the increased number of subjects
exposed to the product after licensure investigators must continue to monitor, evaluate
and characterize the potential adverse events of the product. This will allow for detection
of unexpected adverse events and establish product’s safety profile thus help for decision
making.

Being able to distinguish events that could be potentially related to a vaccine and those
that occur coincidentally is crucial. The quick identification and characterization of any
adverse reactions to the vaccine can help distinguish between causal and no causal
events.
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This investigation will focus on and summarize the potential adverse events following
immunization with PCV13 reported to the Vaccine Adverse Event Reporting System
(VAERS), a national passive surveillance system and primary method to detect vaccine
safety signals. Frequencies of adverse events occurring following immunization with
PCV13 and adverse events previously reported with PCV7 will be compared, taking into
account possible bias, confounding, and probable associations. Although causality
between vaccines and adverse events is not assessed by VAERS, it can detect signals,
unusual or unexpected product-event combinations for more rigorous investigation using
more appropriate epidemiological study designs (Zhou W, et al. 2003).

This examination uses data from a passive surveillance system that has important
limitations and is subject of to both underreporting and over reporting, particularly in the
first year after introduction of a new product (Rosenthal S, et al., 1995). Despite the
limitations, VAERS has played an important role in monitoring adverse events following
immunization. Its ability to detect adverse signals, for example, was demonstrated by
uncovering an association between Rotavirus vaccine (Rotashield®) and Intussusception
(MMWR February 6, 2009 / 58(RR02);1-25). Due to these limitations causality cannot be
determined; other epidemiologic studies must be used for confirmation.

1.1 Background

During pre-licensure randomized clinical trials assessed the safety of both Pneumococcal
conjugated vaccines PCV7 and PCV13, showing favorable results in about 19,000 young
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children who received PCV7 and approximate 5,000 infants who received PCV13 (FDA.
Product approval information–CBER, 2010). At introduction, PCV13 is indicated for
active immunization for the prevention of invasive disease caused by S. pneumoniae
serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F. PCV13 is also indicated
for the prevention of otitis media caused by S. pneumoniae serotypes 4, 6B, 9V, 14, 18C,
19F, and 23F. No otitis media efficacy data are available for serotypes 1, 3, 5, 6A, 7F,
and 19A (FDA, product approval information –CBER, 2010).

In the post-licensure period, a similar safety favorable results was provided for the first
two years of PCV7 when comparing PCV7 to other vaccines after an estimated
distribution of 31.5 million doses of PCV7 within the U.S. Adverse events described in
children younger than 18 years old vaccinated with PCV7 were minor and similar to
those observed in pre-licensure trails (Robert P. Wise et al., 2004). In 2008 a systematic
review of 42 studies regarding the pre-and post-licensure safety profile of pneumococcal
conjugate vaccines did not identify major safety issues with pneumococcal vaccines
(Frank DeStefano et al., 2008). Although some hospitalizations were caused by reactive
airway disease seen in PCV7 and 9-Valent Pneumococcal Conjugate vaccine recipients
compared to controls (Black S et al., 2000 and Klugman et al., 2003) the outcome of
extensive studies in the U.S. did not corroborate such an association (FDA. Product
approval information–CBER, 2010).

The safety profile of PCV13 was assessed in 13 clinical trials; Approximately 15,000
doses were given to 5,000 healthy infants 6 weeks through 15 months of age and the
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comparison group of 2,760 children received at least 1 dose of PCV7. The most
commonly reported adverse reactions (≥20 % of subjects) were redness, swelling and
tenderness at the injection site, fever, decreased appetite, irritability, increased sleep, and
decreased sleep. No imbalance of serious adverse events following vaccination were
observed when compared to PCV7. The most frequently reported local reaction was
tenderness, and the most frequently reported systemic adverse event was irritability. In
the largest U.S. safety study, moderate fever occurred at a statistically significantly
higher rate in PCV13 recipients compared to PCV7 recipients after the second dose. This
finding was not observed in smaller studies. Across all studies, four subjects died due to
sudden infant death syndrome-SIDS (3 received PCV13). There were no consistent trends
identified (FDA. Vaccines: approved products. PCV13).

The severity of local and systemic reactions after vaccination with PCV13 and PCV7
were alike. Thus, the data suggest that the safety profiles of PCV13 and PCV7 were
comparable in pre-licensure studies (MMWR March 12, 2010 / 59(09);258-261),
suggesting that the safety profile of licensed PCV13 will be similar to that of PCV7
vaccine.

1.2 Purpose of Study

This investigation aimed to assess the potential adverse events reported to VAERS
following immunization with PCV13 in the first year of post-licensure and to compare
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clinically significant adverse events following receipt of PCV13 with those that have
been observed after PCV7.
This study will help to ascertain the safety profile of PCV13, detect potential safety
signals that might be of public health importance and the need for additional studies for
clarification and to inform vaccine benefit-risk decision making.

1.3 Research Questions

In order to review the safety profile and investigate the most frequently reported adverse
events after vaccination with PCV13 the following questions must be addressed:

What are the most common adverse events reported to VAERS following immunization
with PCV13 during the first year post-licensure?

What are the frequencies when comparing adverse events of PCV13 with PCV7’s safety
profile?

Are adverse events reported after vaccination with PCV13 the same as those expected
and listed in the package insert?
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CHAPTER II

REVIEW OF THE LITERATURE

2.1 Pneumococcal Vaccines in the U.S.

Worldwide pneumonia is the most common cause of deaths related to pneumococcal
disease. The World Health Organization estimates that approximately 1.9 million
children die each year as a result of an acute respiratory infection, mainly pneumonia.
(Mulholland

K et al., 2003) although this might be an underestimate since the majority of

the childhood deaths occur at home without autopsy. The introduction of new and better
vaccines to protect against pneumococcal disease can have considerable impact in
reducing mortality.

The first pneumococcal vaccine trials began in 1911. The first pneumococcal vaccine was
licensed in the United States in 1977 and included 14 serotypes. In 1983, a 23-valent
pneumococcal polysaccharide vaccine (PPSV23) was licensed and replaced the 14-valent
vaccine. It was recommended for all patients 65 years of age or older and for children 2
years of age or older. However, PPSV23 vaccine immunogenicity was insufficient owing
to a lack of a good T-cell independent immune response and the vaccine was therefore
was less effective in preventing pneumococcal disease in children. A 7-valent conjugate
pneumococcal vaccine (PCV7, Prevnar®) was licensed in the U.S in 2000, using capsular
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polysaccharides from selected serotypes conjugated to a protein carrier to stimulate a Tcell dependent immune response. PCV7 induces both a systemic and mucosal immune
response to prevent nasopharyngeal colonization by bacteria (Edwards et al., 2003).
Ninety pneumococcal serotypes have been identified. It is estimated that about 62% of
invasive disease worldwide is caused by the 10 most common serotypes (Atkinson et al.,
2009). In 2010 the 13-valent pneumococcal vaccine (PCV13, Prevnar 13®) was licensed
in the U.S covering for thirteen serotypes including those in PCV7 vaccine and six
additional serotypes (Table 1).

Table 1. Pneumococcal Vaccines Licensed for Immunization and Distribution in the U.S.
Vaccine

Trade name

Manufactur
er
Merck &
Co, Inc

Year
Licensed
1983

Pneumovax 23 Pneumococcal
Vaccine, Polyvalent

Pneumovax
23®

Pneumococcal 7valent Conjugate
Vaccine (Diphtheria
CRM197 Protein)

Prevnar®

Wyeth
Pharm. Inc

2000

Pneumococcal 13valent Conjugate
Vaccine (Diphtheria
CRM197 Protein)

Prevnar 13®

Wyeth
Pharm. Inc
(acquired
by Pfizer
Inc, 2010)

2010
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Age group
All adults aged ≥65
years and those adults
aged 19--64 years with
underlying medical
conditions that put them
at greater risk for serious
pneumococcal infection
>2 months, ACIP also
recommends children
aged 24--59 months who
are either unvaccinated
or who have a lapse in
PCV7 administration
All children aged 2--59
months. ACIP also
recommends PCV13 for
children aged 60--71
months with underlying
medical conditions that
increase their risk for
pneumococcal disease or
complications

2.2 Pneumococcal vaccines safety studies

There are currently several studies and clinical trials of pneumococcal conjugated
vaccines that provide information on vaccine safety. Furthermore, post-marketing
surveillance for PCV13 is in progress.

The safety of pneumococcal vaccines was established in pre-and post-licensure clinical
trials in different countries. In a clinical trial conducted in South Africa, a 9-valent
pneumococcal conjugate vaccine (PCV9) was administered to approximately 20,000
children with high prevalence of human immunodeficiency virus (HIV). Investigators
reported viral pneumonia being more frequent in children who received the PCV9
vaccine than in children who received placebo; in addition, asthma was found to be more
frequent in PCV9 recipients than in placebo recipients (Klugman et al., 2003). However
in a study of PCV9 conducted in Gambia, asthma was not a frequently reported adverse
event following vaccination (Cutts et al., 2005). In the U.S. the most comprehensive
evaluation of PCV7 during pre-licensure was conducted at Northern California Kaiser
Permanente (NCKP). Adverse events reported after vaccination occurred less frequently
compared to studies previously done in Africa, and asthma was not associated with PCV7
(FDA. Product approval information –CBER, 2010). In the first two years post-licensure
of PCV7, adverse events reported to VAERS in patients less than 18 years old after
immunization with PCV7 were minor and similar to those occurring in pre-licensure
clinical trials (Wise et al., 2004). In a systematic review of 42 studies regarding PCV7
safety profile in several industrialized and developing countries, investigators did not
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identify major safety problems with pneumococcal vaccines (DeStefano et al., 2008).
None of the previous studies found increased risk of death following immunization with
pneumococcal conjugated vaccine and no major safety problems were identified. The
World Health Organization recommended incorporating pneumococcal conjugate vaccine
to all immunization programs (WHO, 2007)

Since the introduction of PCV7 vaccination, invasive pneumococcal disease (IPD) has
decreased in children less than 5 years (Whitney et al., 2006) although an small increase
(about 5 per 100,000) of IPD in the general population was detected and was determined
to be caused by serotype 19A not included in PCV7 vaccine. However since 2002 the
overall rates of IPD have level off to approximate 22-25 cases per 100,000 in children
less than 5 years old (Pilishvili et al., 2010).

2.3 Monitoring Vaccine Safety

The National Childhood Vaccine Injury Act (NCVIA) of 1986 was enacted to manage
the claims of people that reported adverse events or death after immunizations, and thus
help to take care of financial liabilities as well as supervise market supply. The act
required health professionals and vaccine manufacturers to report to the U.S. Department
of Health and Human Services specific adverse events that occur after the administration
of routinely recommended vaccines (National Childhood Vaccine Injury Act of the
Public Health Service).
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The Centers for Disease Control and Prevention (CDC) has vaccine safety post licensure
monitoring systems in place to detect and respond to a potential adverse events following
immunization.

VAERS is a national passive surveillance system and is operated by the CDC and the
Food and Drug Administration (FDA) to accept reports from health care providers,
vaccine manufacturers, the public and others on possible adverse events following
immunization.

2.4 The Vaccine Adverse Events Reporting System (VAERS)

The Vaccine Adverse Events Reporting System (VAERS) is a passive reporting system
used to monitor vaccine safety. It was established in 1990 and is jointly administered by
the Centers for Disease Control and Prevention (CDC) and the Food and Drug
Administration (FDA). VAERS accepts reports of adverse events after vaccination from
vaccine manufacturers, healthcare providers, vaccine recipients, and others. VAERS
generally cannot assess whether a vaccination caused an adverse event, but can identify
possible vaccine safety problems for further investigation (Varricchio F et al., 2004).

VAERS is the largest United States post-licensure surveillance system and has provided
useful information on the safety profile of pneumococcal vaccines in the general
population of children and adults. Because of its size and national scope, VAERS can
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provide information on rare adverse events that may not be detected in pre-licensure
clinical trials.

VAERS serves as the U.S. “early warning” system for potential vaccine safety concerns
(signal detection) about adverse events and reported frequencies compared to what would
be expected to be associated with the use of an specific product (Table 2).

Table 2. Signal Detection
Data
Source
VAERS

Strengths

Limitations

Nationwide
Near real-time
Detection of rare or unexpected events
Lot specific surveillance
Data mining

Underreporting
Consistency
Variable quality of reported information
Specifics on vaccines used
Variable reporting biases
Poorly defined denominators
No controls

VAERS uses the Medical Dictionary for Regulatory Activities (MedDRA) to code the
signs and symptoms about reported adverse events on each report (MedDRA
Maintenance and Support Service Organization). Reports may have multiple MedDRA
codes and might include simultaneous vaccinations.

Reports are classified as serious, based on the Code of Federal Regulations (FDA, 21CFR
314.80) if they result in death, life-threatening illness, hospitalization or prolongation of
hospitalization, permanent disability, or if a congenital anomaly is reported (FDA.,
Postmarketing reporting of adverse experiences; 1997). All serious events are reviewed.
15

This regulatory definition of a serious report does not always reflect the severity of an
outcome. Reports are usually submitted by electronic mail by accessing
http://www.vaers.org, regular mail or fax. All serious adverse events and deaths are
followed up by FDA and CDC medical officers and epidemiologists.

2.5 Recommendations for 13-Valent Pneumococcal Conjugate vaccine

PCV13 is part of the U.S recommended immunization schedule for persons aged 0
through 6 years (Figure 1). PCV13 is approved for use among children aged 6 weeks--71
months and recommended as a four dose series at ages 2, 4, 6, and 12-15 months. PCV13
will succeed PCV7. On February 24, 2010, PCV13 was recommended (MMWR
December 10, 2010 / 59(RR11);1-18) by the Advisory Committee on Immunization
Practices (ACIP) for routine vaccination of:
•

All children aged 2--59 months (Appendix A: Tables 3, 4 and 5).

•

Children aged 60--71 months with underlying medical conditions that increase their
risk for pneumococcal disease or complications (Appendix A: Table 6).

•

Children who previously received 1 or more doses of PCV7.

•

Unvaccinated children and children incompletely vaccinated with PCV7-- Transition
from PCV7 to the PCV13 immunization program (Appendix A: Table 7)
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Chapter III

METHODOLOGY

3.1 Data Source

We searched and reviewed reports of adverse events after PCV13 submitted to the
Vaccine Adverse Event Reporting System (VAERS).

We searched for reports received by February 24, 2011 for persons vaccinated with
PCV13 from February 24, 2010 through December 31, 2010. In order to assess the
reporting trends and whether the proportions of reports received after PCV13
immunization were similar to PCV7 in previous years we went back avoiding seasonal
pattern and reviewed safety data, U.S VAERS reports for adverse events reported
following PCV7 from February 24, 2000 through February 24, 2001, persons vaccinated
with PCV7 from February 24, 2000 through December 31, 2000. The total number of
adverse events was stratified for PCV13 and PCV7. The numbers of deaths, non-fatal
serious and non-serious reports were determined. Non-US reports were excluded.

We used information from VAERS which included demographics on the recipient (age,
sex, etc,), type of vaccine, vaccination date, manufacturer, vaccine lot number, doses
previously received, date of onset of symptoms and description of the event. Onset
interval is the number of days from the time of vaccination to the onset of earliest
reported symptoms.
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Crude reporting rates for VAERS adverse events per 100,000 doses of vaccine were
calculated by dividing the number of events occurring within the 12 months after PCV13
vaccination by total doses of PCV13 vaccine distributed in the United States. To calculate
reporting rates, distribution data (total doses of PCV13 vaccine distributed) provided by
vaccine manufacturer were used as an estimate of total doses administered to U.S. and as
“denominator” to estimate reporting rates.

Based on pre- and post-licensure safety data on pneumococcal conjugate vaccines,
special attention was paid to respiratory events that followed PCV13 vaccination
including reactive airway disease and asthma (DeStefano F et al.,2008). A pre-specified
group of combined MedDRA preferred terms was used as a search criterion to select
potential asthma and reactive airway disease reports (bronchospasm, wheezing, asthma,
status asthmaticus, reversible airway obstruction, bronchial hyper reactivity, asthmatic
crisis, infantile asthma and respiratory distress).

3.2 Statistical Analysis

Descriptive statistics were used to describe the epidemiology of reports submitted to the
VAERS, a national passive surveillance database for the U.S.
The VAERS database use standardized coding terms that are assigned after review of
each report by trained personnel. Most reports receive multiple codes.
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Because VAERS is a routine surveillance program that does not meet the definition of
research, it is not subject to Institutional Review Board review and informed consent
requirements.
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Chapter IV

RESULTS

4.1 Frequencies and Descriptive Statistics

From February 24, 2010, through February 24, 2011, VAERS received 1,503 reports of
adverse events following receipt of PCV13; 180/1,503 or 11.9% reports were described
as serious including 19 fatalities and most of the reports were described as non-serious
(1,323/1,503 or 88%). From February 24, 2000, through February 24, 2001, a total of 963
reports were received after PCV7 vaccination; 114 (11.8%) were serious; including 23
reports of death, and 849 (88%) reports were non-serious. The number of death reports
received over the first year after PCV13 licensure (19/1,503 or 1.3%) was less than the
first post licensure year for the PCV7 group (23/963 or 2.4%). The percentage of serious
reports after vaccination with PCV13 was lower compared to PCV7 (Table 8).

Among all, the most frequently reported adverse events following immunization were
injection site erythema (25.5%, 15.2%), pyrexia (24.2%, 32.0%) and injection site
swelling (19.4%, 5.5%) for PCV13 and PCV7, respectively (Table 9). Other common
adverse events reported after PCV13 were irritability, injection site pain and vomiting.
No unexpected serious events or death appeared to be associated with PCV13 or PCV7.
In the analysis among serious reports, pyrexia (38.9%, 28.9%), irritability (36.1%,
11.4%) and vomiting (35.6%, 8.8%) were the most frequently reported adverse events for
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PCV13 and PCV7, respectively (Table 10). The median age (<1 year) were the same for
PCV13 and PCV7 whereas the median onset interval was 2 and 1 day for PCV13 and
PCV7 respectively.

The percentage of persons receiving the pneumococcal vaccine alone with no other
antigens was higher for PCV13 compared to PCV7; In 323 of 1,503 reports (21%)
PCV13 was the only vaccine administered, the remaining 79% of reports described
simultaneous vaccination of PCV13 with a variety of other vaccines. Whereas 324 of 963
reports (34%) noted PCV7 administration without simultaneous vaccinations.

Most of the adverse events reported in both groups happened within one day of
vaccination. For PCV13, of the 1380 reports that included onset interval, 545 (36%)
occurred on the day of vaccination compared to PCV7 reports whereas 927 reports
including onset interval, 347 (36%) occurring the same day of vaccination. The median
age of recipients reporting adverse events to VAERS after immunization with PCV13 and
PCV7 was the same (<1 year). 50% (758/1503) and 51% (493/963) of reports received
were in males for PCV13 and PCV7, respectively; for the PCV13 reports, 48% were in
females and 1% were reports with unspecified gender whereas for the PCV7, 45% were
in females and 3% reports had unspecified gender.

There were no significant differences in reporting practices to VAERS by recipients. The
majority of reports following PCV13 (941/1503, or 63%) were submitted by the
healthcare provider, compared to 39% reports submitted by providers after vaccination
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with PCV7. Other additional sources of reporting included manufacturer (7%, 23%),
patients or parents (4%, 3%), state health clinics (3%, 6%), and “others” (23%, 3%) for
PCV13 and PCV7, respectively. The proportions of reported adverse events found for all
reports received after vaccination with PCV13 were lower for calculated age group <6
months and 6-11 months (22% and 10% vs. 25% and 22%) compared to PCV7; for the
calculated age group 3-5 years the proportion was greater (29% vs. 8%) compared to
PCV7.

Table 8. Characteristics of the Vaccine Adverse Event Reporting System (VAERS) U.S.
reports following receipt of PCV13 vaccine February 24, 2010 through February 24,
2011 (n=1503) and PCV7 vaccine February 24, 2000 through February 24, 2001 (n=963)
Characteristic
All reports
Serious reports
Deaths
Recipients age in years a (median [range])
Onset interval in days b (median [range])
Male reports c
Vaccine given alone
Reports with MedDRA d term coded for
“wheezing”
Reports with MedDRA d term coded for
“asthma” e
Age group

PCV13
n=1503
11.9% (180/1503)
1.2% (19/1503)
1.0 (0 – 75.0)
1.0 (0 – 91.0)
50.4% (758/1503)
21.0% (323/1503)

PCV7
n=963
11.8% (114/963)
2.4% (23/963)
1.0 (0 – 80.0)
1.0 (0 – 204.0)
51.1% (493/963)
33.6% (324/963)

2.1 % (31/1503)

0.7% (7/963)

2.4 % (36/1503)

0.9 % (9/963)

< 6 mos
6-11 mos
1-2 years
3-5 years
>=6 years
Unknown

21.6% (325/1503)
9.5% (143/1503)
37.7% (567/1503)
28.8% (433/1503)
0.68% (11/1503)
1.6% (25/1503)

25.3% (244/963)
22.1% (213/963)
41.3% (398/963)
7.6% (74/963)
1.8% (18/963)
1.6% (16/963)

a

Age unknown for 25 and 16 reports for PCV13 and PCV7 respectively.
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b

Onset unknown for 123 and 36 reports for PCV13 and PCV7 respectively. Days from
the time of vaccination to the onset of the earliest reported symptoms.
c

Gender unknown for 21 and 32 reports for PCV13 and PCV7 respectively.

d

The Medical Dictionary for Regulatory Activities (MedDRA) was used to code
symptoms and/or conditions described in each report.
e

Asthma Combined MedDRA PTs: Bronchospasm, wheezing, asthma, status
asthmaticus, reversible airway obstruction, bronchial hyperreactivity, asthmatic crisis,
infantile asthma, respiratory distress.

Table 9. Most common reported frequencies of adverse events occurring after
vaccination with PCV13 (PCV13) and PCV7 (Prevnar®); ALL reports.

Reported frequencies of adverse events occurring following
administration of PCV13 and PCV7—All reports
%
PCV 13*
PCV 7†
(n = 1,503) (n = 963)
Injection site erythema
25.5
15.2
Pyrexia
24.2
32.0
Injection site swelling
19.4
5.5
irritability
10.3
11.1
Injection site pain
9.8
5.5
Injection site warmth
9.8
3.5
Vomiting
9.2
6.7
Urticaria
7.5
10.0
Crying
7.4
3.7
Erythema
6.5
3.7
Rash
6.3
8.7
Body temperature increased
5.8
-Injection site duration
5.2
2.9
Abbreviations: PCV13 = 13-valent pneumococcal polysaccharideprotein conjugate vaccine, PCV7 = 7-valent pneumococcal
polysaccharide-protein conjugate vaccine, and NA = data not available.
Adverse event

* ALL VAERS reports received following PCV13 immunization
2/24/10 through 2/24/11; vaccination date 2/24/10 through 12/31/10.
† ALL VAERS reports received following PCV7 immunization 2/24/00
through 2/24/01; vaccination date 2/24/00 through 12/31/00.
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Table 10. Most common reported frequencies of Serious adverse events occurring after
vaccination with PCV13 (PCV13) and PCV7 (Prevnar®)

Reported frequencies of adverse events occurring following administration of PCV13
and PCV7—Serious reports
PCV 13* (n=180)
Adverse Event
PYREXIA

%

PCV 7† (n=114)
Adverse Event

%

PYREXIA

IRRITABILITY

38.9
36.1

CONVULSION

28.9
20.2

VOMITING

35.6

APNOEA

12.3

BLOOD CULTURE NEGATIVE

22.8

IRRITABILITY

11.4

INTUSSUSCEPTION

20.6
19.4

LETHARGY
CYANOSIS

10.5
9.6

DIARRHOEA

18.9

VOMITING

8.8

UNRESPONSIVE TO STIMULI

16.1

ANOREXIA

8.8

COUGH

16.1

SUDDEN INFANT DEATH SYNDROME

8.8

15.6

COMA

7
7

CONVULSION

PLATELET COUNT INCREASED
ULTRASOUND ABDOMEN ABNORMAL

15.6

BACTERIAL INFECTION

CRYING

15.6

HYPOTONIA

7

WHITE BLOOD CELL COUNT INCREASED

13.9

PNEUMONIA

7

ENEMA ADMINISTRATION

12.8

FEBRILE CONVULSION

5.3
5.3

CULTURE URINE NEGATIVE

12.8

SOMNOLENCE

LYMPHOCYTE PERCENTAGE
DECREASED
SOMNOLENCE

12.2

PALLOR

5.3

12.2

RASH

5.3

HAEMATOCRIT DECREASED

LABORATORY TEST ABNORMAL

CHEST X-RAY ABNORMAL

12.2
12.2

CARDIAC ARREST

4.4
4.4

ELECTROENCEPHALOGRAM NORMAL

12.2

UPPER RESPIRATORY TRACT INFECTION

3.5

GAZE PALSY

12.2

DEHYDRATION

3.5

CHEST X-RAY NORMAL

12.2

AGITATION

3.5

HAEMATOCHEZIA

11.7
11.7
11.7

UNEVALUABLE EVENT

3.5
3.5
3.5

NEUTROPHIL PERCENTAGE INCREASED
COMPUTERISED TOMOGRAM NORMAL

STUPOR
STARING

Abbreviations: PCV13=13-valent pneumococcal polysaccharide-protein conjugate
vaccine, PCV7= 7-valent pneumococcal polysaccharide-protein conjugate vaccine.
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* Serious VAERS reports received following PCV13 immunization 2/24/10 through
2/24/11; vaccination date 2/24/10 through 12/31/10.
† Serious VAERS reports received following PCV7 immunization 2/24/00 through
2/24/01; vaccination date 2/24/00 through 12/31/00.
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Chapter V

DISCUSSION AND CONCLUSION

5.1 Discussion

In the pre-licensure safety database, which includes approximately 15,000 doses and
5,000 recipients, no safety signals were identified. The available post-marketing data
support an acceptable safety profile for PCV13. The great majority of reports in the first
year after PCV13 licensure described minor signs and symptoms previously documented
during clinical trials. The proportion of reports describing serious events (11.9%) was
similar to that reported on a regular basis for other vaccines in the data system (14.3%)
(Zhou W, et al. 2003). Nonetheless, further investigation for unusual reports of serious
events (i.e. seizures), including requesting medical records for clinical review and follow
up, continues to be a priority.

Although the total number of VAERS reports received following PCV13 vaccination was
higher than the total reports received following PCV7 vaccination for all age groups in
the previous year, the findings must be carefully interpreted since enhanced reporting to
VAERS has been documented when a new vaccine is licensed and available to the public.
In addition, an increase in adverse events that may attributable in part to heightened
public perception and awareness (Zhou W et al., 2003). Finally, each VAERS report
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usually includes multiple MedDRA codes and occasional duplicate coding or coding
errors may appear, also many reported events may not be due to the vaccine.

Asthma and reactive airway disease have been found statistically important in previous
pneumococcal studies (Klugman et al., 2003). This investigation looked for asthma and
reactive airway disease reports using pre-specified MedDRA codes and demonstrated no
difference in proportional reporting after PCV13 vaccination compared with PCV7
vaccine. Local reactions are very common after vaccination of any type and very often
occur with minor symptoms and with no sequelae. Expected reports of pyrexia as a
frequent adverse event were observed, however findings were similar in both groups and
similar to previous studies of these vaccines. Fever is also a common symptom in
children and not necessarily related to vaccination.

5.2 Study Limitations

VAERS is a passive surveillance system with limitations that include both underreporting and biased reporting that can affect the outcome and analysis. More important,
VAERS generally does not assess causality. Because VAERS accepts reports from any
person, it is common to find duplicates or errors in reporting as well as missing data (i.e.
demographics) in some cases. However VAERS has been used as an important
surveillance tool and demonstrated to be very helpful when assessing vaccine safety

27

(MMWR February 6, 2009 / 58(RR02);1-25) and has a national capacity that permitted
us to investigate in a large and diverse population.

This study assessed associations between adverse event reported to VAERS after
vaccination with PCV13, however for a stricter and deeper analysis of direct associations
of vaccination and adverse events an exhaustive clinical review of each serious report
will be necessary to rule out similar reported clinical symptoms and signs in order to be
able to establish cases and their association with safety concerns. Another limitation was
the inability to calculate adjusted reporting rates for selected adverse events.

5.3 Recommendations

1. More surveillance and multidisciplinary approaches are needed to address the
limitations of VAERS. Clinical review of medical records would help to understand
better the nature of the adverse events reported.

2. Health professionals, health care providers and policy makers must develop and
implement interventions to spread the knowledge to the general public regarding the
safety of the vaccines as well as let people know about systems that are in place for
continue monitoring vaccine safety issues in addition to insist in the benefits of and
the need for immunizations against vaccine preventable diseases.
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3. Encourage all healthcare personnel and public in general to use the VAERS system to
report any clinically significant medical event that occurs after vaccination, even if
the reporter cannot be sure that the event was caused by the vaccine. If no minor
adverse event is unreported, the better the data captured and the higher the probability
for a correct assessment, increasing the availability of information and continued
monitoring of the safety of the PCV13 are key for ensuring optimal public health
decisions and public confidence in the Pneumococcal 13-valent Conjugate Vaccine.

5.4 Conclusion

We were able to compare PCV13 and PCV7 risk profile. Among all reports, frequencies
of solicited adverse events after vaccination with PCV13 were similar to those reported in
prior studies and those currently listed in the package insert. No unexpected adverse
events reported after PCV13 vaccination.

The safety profile of the PCV13 needs to be considered in the context of the benefits of
vaccination, which includes the disease epidemiology and the vaccine effectiveness.
Education about the recommendations, safety and importance of immunization with
pneumococcal vaccines is fundamental to decrease disease rates.
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APPENDIX A: Recommended schedule for use of PCV13

Table 3. Recommended schedule for use of 13-valent pneumococcal conjugate vaccine

Recommended schedule for use of 13-valent pneumococcal conjugate vaccine (PCV13) among
previously unvaccinated infants and children by age at time of first vaccination
Primary PCV13
Age at first dose (mos)
PCV13 booster dose†
series*
2--6
3 doses
1 dose at 12--15 mos
7--11
2 doses
1 dose at 12--15 mos
12--23
2 doses
NA
24--59 in healthy children
1 dose
NA
24--71 in children with certain chronic
2 doses
NA
diseases or immunocompromising conditions§
Abbreviation: NA = not applicable
* Minimum interval between doses is 8 weeks except for children vaccinated at age <12 months,
for whom minimum interval between doses is 4 weeks. Minimum age for administration of first
dose is 6 weeks.
† Administered at least 8 weeks after the previous dose.
§ See Table 6 for a complete list of conditions.

Table 4. Recommended schedule for use of 13-valent pneumococcal conjugate vaccine

Recommended schedule for administering doses of 13-valent pneumococcal conjugate vaccine
(PCV13) to children aged <24 months by PCV vaccination history and age --- Advisory
Committee on Immunization Practices, US, 2010
Vaccination history: total
Age at this visit
number of PCV7 and/or
Recommended PCV13 regimen*
PCV13 doses received
(mos)
previously
2--6 mos
0 doses
3 doses, 8 weeks apart; fourth dose at
age 12--15 mos
1 dose
2 doses, 8 weeks apart; fourth dose at
age 12--15 mos
2 doses
1 dose, 8 weeks after the most recent
dose; fourth dose at age 12--15 mos
7--11 mos
0 doses
2 doses, 8 weeks apart; third dose at 12-15 mos
1 or 2 doses before age 7 mos 1 dose at age 7--11 mos, with a second
dose at 12--15 mos, ≥8 weeks later
12--23 mos
0 doses
2 doses, ≥8 weeks apart
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1 dose before age 12 mos
1 dose at ≥12 mos

2 doses, ≥8 weeks apart
1 dose, ≥8 weeks after the most recent
dose†
1 dose,≥8 weeks after the most recent
dose†
1 supplemental dose ≥8 weeks after the
most recent dose

2 or 3 doses before age 12
mos
4 doses of PCV7 or other ageappropriate, complete PCV7
schedule
Abbreviation: PCV7 = 7-valent pneumococcal polysaccharide-protein conjugate vaccine.
* Minimum interval between doses is 8 weeks except for children vaccinated at age <1 year, for
whom minimum interval between doses is 4 weeks.
† No additional PCV13 doses are indicated for children aged 12--23 months who have received
2 or 3 doses of PCV7 before age 12 months and at least 1 dose of PCV13 at age ≥12 months.

Table 5. Recommended schedule for use of 13-valent pneumococcal conjugate vaccine

Recommended schedule for administering doses of 13-valent pneumococcal conjugate vaccine
(PCV13) to children aged ≥24 months by PCV vaccination history and age
Age at this visit
(mos)
24--59 mos in
healthy children

24--71 mos in
children with
underlying
medical
conditions†

Vaccination history: total
number of PCV7 and/or
PCV13 doses received
previously before age 24
months
Unvaccinated or any
incomplete schedule
4 doses of PCV7 or other
age-appropriate, complete
PCV7 schedule
Unvaccinated or any
incomplete schedule of <3
doses

Recommended PCV13 regimen*

1 dose, ≥ 8 weeks after the most recent dose
1 supplemental dose, ≥8 weeks after the most
recent dose
2 doses, the first dose ≥8 weeks after the most
recent dose and a second dose ≥ 8 weeks later

Any incomplete schedule of 1 dose, ≥ 8 weeks after the most recent dose
3 doses
4 doses of PCV7 or other
1 supplemental dose, ≥8 weeks after the most
age-appropriate complete
recent dose
PCV7 schedule
Abbreviation: PCV7 = 7-valent pneumococcal polysaccharide-protein conjugate vaccine.
* Minimum interval between doses is 8 weeks.
† For list of conditions, see Table 6.
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Table 6. Underlying medical conditions that are indications for pneumococcal
vaccination
Underlying medical conditions that are indications for pneumococcal vaccination among
children, by risk group --- Advisory Committee on Immunization Practices (ACIP), United
States, 2010
Risk group
Condition
Immunocompetent
children

Children with functional or
anatomic asplenia
Children with
immunocompromising
conditions

Chronic heart disease*
Chronic lung disease†
Diabetes mellitus
Cerebrospinal fluid leaks
Cochlear implant
Sickle cell disease and other hemoglobinopathies
Congenital or acquired asplenia, or splenic dysfunction
HIV infection
Chronic renal failure and nephrotic syndrome
Diseases associated with treatment with immunosuppressive drugs
or radiation therapy, including malignant neoplasms, leukemias,
lymphomas, and Hodgkin disease; or solid organ transplantation
Congenital immunodeficiency§

* Particularly cyanotic congenital heart disease and cardiac failure.
† Including asthma if treated with prolonged high-dose oral corticosteroids.
§ Includes B- (humoral) or T-lymphocyte deficiency; complement deficiencies, particularly C1,
C2, C3, and C4 deficiency; and phagocytic disorders (excluding chronic granulomatous disease).

Table 7. Recommended transition schedule
Recommended transition schedule from 7-valent pneumococcal conjugate vaccine (PCV7) to
13-valent vaccine (PCV13) vaccination among infants and children, according to number of
previous PCV7 doses received --- Advisory Committee on Immunization Practices (ACIP),
United States, 2010
Infant series
Booster
Supplemental
dose
PCV13 dose
2 mos

4 mos

6 mos

≥12 mos*

14--59 mos†

PCV7

PCV13

PCV13

PCV13

---

PCV7

PCV7

PCV13

PCV13

---

PCV7

PCV7

PCV7

PCV13

---

PCV7

PCV7

PCV7

PCV7

PCV13

* No additional PCV13 doses are indicated for children age 12--23 months who have received 2
or 3 doses of PCV before age 12 months and at least 1 dose of PCV13 at age ≥12 months.
† For children with underlying medical conditions (see Table 6), a single supplemental PCV13
dose is recommended through age 71 months
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FIGURE 1: Recommended immunization schedule for persons aged 0 through 6
years, U.S, 2011
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